SCHEMBL6565854

SCHEMBL6565854

CCC(=O)c1cc(NC(=O)Nc2ccccc2)ccc1OC(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.46
MEN1 O00255 5/20 0.46
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
NOX1 Q9Y5S8 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 4/20 0.42
GAA P10253 1/20 0.42
HIF1A Q16665 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
HTT P42858 1/20 0.41
RORC P51449 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6564383 0.92 CASR (0.50) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL6564522 0.91 KMT2A (0.51) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL6567509 0.90 CASR (0.53) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6564429 0.86 KMT2A (0.49) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6564786 0.85 KMT2A (0.61) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6568006 0.84 KCNB1 (0.43) KMT2AMEN1LMNASMN1; SMN2MAPT
SCHEMBL6566966 0.83 TP53 (0.43) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6565846 0.83 MEN1 (0.52) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6564651 0.82 NPSR1 (0.46) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL6564631 0.82 EPHX1 (0.47) ALDH1A1HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-12-23 US disclosed
EP-1437344-A1 BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259912-A1 Benzine derivatives, process for preparing the same and use thereof HRH4, HRH2, HRH1 KMT2A 3137/4885MEN1 4143/4885LMNA 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.